Therapeutic efficacy of bone marrow‐derived mononuclear cells in diabetic polyneuropathy is impaired with aging or diabetes. Issue 2 (11th September 2014)

• Record Type: Journal Article
• Authors: Kondo, Masaki; Kamiya, Hideki; Himeno, Tatsuhito; Naruse, Keiko; Nakashima, Eitaro; Watarai, Atsuko; Shibata, Taiga; Tosaki, Takahiro; Kato, Jiro; Okawa, Tetsuji; Hamada, Yoji; Isobe, Ken‐ichi; Oiso, Yutaka; Nakamura, Jiro
• Is Part Of: Journal of diabetes investigation. Volume 6:Issue 2(2015:Apr.)
• Page Start: 140
• Page End: 149
• Publication Date: 2014-09-11
• Subjects: Diabetes -- Periodicals; Diabetes -- Research -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462005
• DOI: 10.1111/jdi.12272
• Languages: English
• ISSNs: 2040-1116

Abstract

<abstract abstract-type="main" id="jdi12272-abs-0001"> <title>Abstract</title> <sec id="jdi12272-sec-0001" sec-type="section"> <title>Aims/Introduction</title> <p>Recent studies have shown that cell transplantation therapies, such as endothelial precursor cells, bone marrow‐derived mononuclear cells (BM‐MNCs) and mesenchymal stem cells, are effective on diabetic polyneuropathy through ameliorating impaired nerve blood flow in diabetic rats. Here, we investigated the effects of BM‐MNCs transplantation in diabetic polyneuropathy using BM‐MNCs derived from adult (16‐week‐old) diabetic (AD), adult non‐diabetic (AN) or young (8‐week‐old) non‐diabetic (YN) rats.</p> </sec> <sec id="jdi12272-sec-0002" sec-type="section"> <title>Materials and Methods</title> <p>BM‐MNCs of AD and AN were isolated after an 8‐week diabetes duration. The BM‐MNCs were characterized using flow cytometry analysis of cell surface markers and reverse transcription polymerase chain reaction of several cytokines. BM‐MNCs or saline were injected into hind limb muscles. Four weeks later, the thermal plantar test, nerve conduction velocity, blood flow of the sciatic nerve and capillary‐to‐muscle fiber ratio were evaluated.</p> </sec> <sec id="jdi12272-sec-0003" sec-type="section"> <title>Results</title> <p>The number of CD29<sup>+</sup>/CD90<sup>+</sup> cells that host mesenchymal stem cells in BM‐MNCs decreased in AD compared with AN or YN, and transcript expressions of basic fibroblast growth factor and nerve growth factor in BM‐MNCs decreased in AD compared with AN or YN. Impaired thermal sensation, decreased blood flow of the sciatic nerve and delayed nerve conduction velocity in 8‐week‐diabetic rats were significantly ameliorated by BM‐MNCs derived from YN, whereas BM‐MNCs from AD or AN rats did not show any beneficial effect in these functional tests.</p> </sec> <sec id="jdi12272-sec-0004" sec-type="section"> <title>Conclusions</title> <p>These results show that cytokine production abilities and the mesenchymal stem cell population of BM‐MNCs would be modified by aging and metabolic changes in diabetes, and that these differences could explain the disparity of the therapeutic efficacy of BM‐MNCs between young and adult or diabetic and non‐diabetic patients in diabetic polyneuropathy.</p> </sec> </abstract>